A locus on chromosome 9p confers susceptibility to ALS and frontotemporal dementia
Abstract
Objective: To perform genetic linkage analysis in a family affected with ALS and frontotemporal dementia (FTD).
Methods: The authors performed a genome-wide linkage analysis of a four-generation, 50-member Scandinavian family in which five individuals were diagnosed with ALS and nine with FTD. Linkage calculations assuming autosomal dominant inheritance of a single neurodegenerative disease manifesting as either ALS or FTD with age-dependent penetrance were performed. Further analyses for ALS alone and FTD alone were performed. A parametric logarithm of odds (lod) score of 2.0 or greater was required for further study of a potential locus and crossover (haplotype) analysis.
Results: A new ALS-FTD locus was identified between markers D9s1870 and D9s1791 on human chromosome 9p21.3-p13.3. A maximum multipoint lod score of 3.00 was obtained between markers D9s1121 and D9s2154. Crossover analysis indicates this region covers approximately 21.8 cM, or 14Mb.
Conclusions: A locus on chromosome 9p21.3-p13.3 is linked to ALS-FTD.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Kurland LT, Mulder DW. Epidemiological investigations of amyotrophic lateral sclerosis: familial aggregations indicative of autosomal dominant inheritance, parts I and II. Neurology 19555;182–196.
2.
Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 1995;118(Pt 3):707–719.
3.
Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis [published erratum appears in 1993;364:362] [see comments]. Nature 1993;362:59–62.
4.
Hentati A, Ouahchi K, Pericak-Vance MA, et al. Linkage of a commoner form of recessive amyotrophic lateral sclerosis to chromosome 15q15-q22 markers [in process citation]. Neurogenetics 1998;2:55–60.
5.
Hand CK, Khoris J, Salachas F, et al. A novel locus for familial amyotrophic lateral sclerosis, on chromosome 18q. Am J Hum Genet 2002;70:251–256.
6.
Ruddy DM, Parton MJ, Al-Chalabi A, et al. Two families with familial amyotrophic lateral sclerosis are linked to a novel locus on chromosome 16q. Am J Hum Genet 2003;73:390–396.
7.
Sapp PC, Hosler BA, McKenna-Yasek D, et al. Identification of two novel loci for dominantly inherited familial amyotrophic lateral sclerosis. Am J Hum Genet 2003;73:397–403.
8.
Abalkhail H, Mitchell J, Habgood J, Orrell R, De Belleroche J. A new familial amyotrophic lateral sclerosis locus on chromosome 16q12.1-16q12.2. Am J Hum Genet 2003;73:383–389.
9.
Puls I, Jonnakuty C, LaMonte BH, et al. Mutant dynactin in motor neuron disease. Nat Genet 2003;33:455–456.
10.
Chen YZ, Bennett CL, Huynh HM, et al. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am J Hum Genet 2004;74:1128–1135.
11.
Nishimura AL, Mitne-Neto M, Silva HC, et al. A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am J Hum Genet 2004;75.
12.
Hadano S, Hand CK, Osuga H, et al. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat Genet 2001;29:166–173.
13.
Yang Y, Hentati A, Deng HX, et al. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat Genet 2001;29:160–165.
14.
Eymard-Pierre E, Lesca G, Dollet S, et al. Infantile-onset ascending hereditary spastic paralysis is associated with mutations in the alsin gene. Am J Hum Genet 2002;71:518–527.
15.
Devon R, Helm J, Rouleau G, et al. The first nonsense mutation in alsin results in a homogeneous phenotype of infantile-onset ascending spastic paralysis with bulbar involvement in two siblings. Clin Genet 2003;64:210–215.
16.
Chow TW, Miller BL, Hayashi VN, Geschwind DH. Inheritance of frontotemporal dementia. Arch Neurol 1999;56:817–822.
17.
Kertesz A, Munoz DG. Primary progressive aphasia [review]. Clin Neurosci 1997;4:95–102.
18.
Snowden JS, Neary D, Mann DM. Frontotemporal dementia. Br J Psychiatry 2002;180:140–143.
19.
Mitsuyama Y. Presenile dementia with motor neuron disease in Japan: clinico-pathological review of 26 cases. J Neurol Neurosurg Psychiatry 1984;47:953–959.
20.
Mitsuyama Y, Kogoh H, Ata K. Progressive dementia with motor neuron disease. An additional case report and neuropathological review of 20 cases in Japan. Eur Arch Psychiatry Neurol Sci 1985;235:1–8.
21.
Neary D, Snowden JS, Mann DM, Northen B, Goulding PJ, Macdermott N. Frontal lobe dementia and motor neuron disease. J Neurol Neurosurg Psychiatry 1990;53:23–32.
22.
Caselli RJ, Windebank AJ, Petersen RC, et al. Rapidly progressive aphasic dementia and motor neuron disease [see comments]. Ann Neurol 1993;33:200–207.
23.
Morita K, Kaiya H, Ikeda T, Namba M. Presenile dementia combined with amyotrophy: a review of 34 Japanese cases. Arch Gerontol Geriatr 1987;6:263–277.
24.
Peavy GM, Herzog AG, Rubin NP, Mesulam MM. Neuropsychological aspects of dementia of motor neuron disease: a report of two cases. Neurology 1992;42:1004–1008.
25.
Abrahams S, Goldstein LH, Kew JJM, et al. Frontal lobe dysfunction in amyotrophic lateral sclerosis. A PET study. Brain 1996;119:2105–2120.
26.
Abrahams S, Leigh PN, Goldstein LH. Cognitive change in ALS: a prospective study. Neurology 2005;64:1222–1226.
27.
Jackson M, Lennox G, Lowe J. Motor neurone disease-inclusion dementia. Neurodegeneration 1996;5:339–350.
28.
Massman PJ, Sims J, Cooke N, Haverkamp LJ, Appel V, Appel SH. Prevalence and correlates of neuropsychological deficits in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 1996;61:450–455.
29.
Lomen-Hoerth C, Murphy J, Langmore S, Kramer JH, Olney RK, Miller B. Are amyotrophic lateral sclerosis patients cognitively normal? Neurology 2003;60:1094–1097.
30.
Abrahams S, Goldstein LH, Al-Chalabi A, et al. Relation between cognitive dysfunction and pseudobulbar palsy in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 1997;62:464–472.
31.
Abrahams S, Leigh PN, Harvey A, Vythelingum GN, Grise D, Goldstein LH. Verbal fluency and executive dysfunction in amyotrophic lateral sclerosis (ALS). Neuropsychologia 2000;38:734–747.
32.
Hosler BA, Siddique T, Sapp PC, et al. Linkage of familial amyotrophic lateral sclerosis with frontotemporal dementia to chromosome 9q21-q22. JAMA 2000;284:1664–1669.
33.
Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Available at: http://www.wfnals.org/Articles/elescorial1998.htm.
34.
Gunnarsson LG, Dahlbom K, Strandman E. Motor neuron disease and dementia reported among 13 members of a single family. Acta Neurol Scand 1991;84:429–433.
35.
The Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry 1994;57:416–418.
36.
Bigio EH, Johnson NA, Rademaker AW, et al. Neuronal ubiquitinated intranuclear inclusions in familial and non-familial frontotemporal dementia of the motor neuron disease type associated with amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2004;63:801–811.
37.
Takahashi T, Yagishita S, Amano N, Yamaoka K, Kamei T. Amyotrophic lateral sclerosis with numerous axonal spheroids in the corticospinal tract and massive degeneration of the cortex. Acta Neuropathol 1997;94:294–299.
38.
Maekawa S, Al-Sarraj S, Kibble M, et al. Cortical selective vulnerability in motor neuron disease: a morphometric study. Brain 2004;127(Pt 6):1237–1251.
39.
Kew JJ, Goldstein LH, Leigh PN, et al. The relationship between abnormalities of cognitive function and cerebral activation in amyotrophic lateral sclerosis. A neuropsychological and positron emission tomography study. Brain. 1993;116(Pt 6):1399–1423.
40.
Ellis CM, Suckling J, Jr AE, et al. Volumetric analysis reveals corticospinal tract degeneration and extramotor involvement in ALS. Neurology 2001;57:1571–1578.
41.
Lloyd CM, Richardson MP, Brooks DJ, Al-Chalabi A, Leigh PN. Extramotor involvement in ALS: PET studies with the GABA(A) ligand [(11)C]flumazenil. Brain 2000;123(Pt 11):2289–2296.
42.
Kato S, Hayashi H, Yagishita A. Involvement of the frontotemporal lobe and limbic system in amyotrophic lateral sclerosis: as assessed by serial computed tomography and magnetic resonance imaging. J Neurol Sci 1993;116:52–58.
43.
Kiernan JA, Hudson AJ. Frontal lobe atrophy in motor neuron diseases. Brain. 1994;117(Pt 4):747–757.
44.
Kovari E, Leuba G, Savioz A, et al. Familial frontotemporal dementia with ubiquitin inclusion bodies and without motor neuron disease. Acta Neuropathol (Berl) 2000;100:421–426.
45.
Bigio EH, Lipton AM, WhiteCL 3rd, Dickson DW, Hirano A. Frontotemporal and motor neurone degeneration with neurofilament inclusion bodies: additional evidence for overlap between FTD and ALS. Neuropathol Appl Neurobiol 2003;29:239–253.
46.
Tolnay M, Probst A. Frontal lobe degeneration: novel ubiquitin-immunoreactive neurites within frontotemporal cortex. Neuropathol Appl Neurobiol 1995;21:492–497.
47.
Skibinski G, Parkinson NJ, Brown JM, et al. Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat Genet 2005;37:806–808.
48.
Watts GD, Wymer J, Kovach MJ, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet 2004;36:377–381.
49.
Bertram L, Hiltunen M, Parkinson M, et al. Family-based association between Alzheimer’s disease and variants in UBQLN1. N Engl J Med 2005;352:884–894.
50.
DeChiara TM, Vejsada R, Poueymirou WT, et al. Mice lacking the CNTF receptor, unlike mice lacking CNTF, exhibit profound motor neuron deficits at birth. Cell 1995;83:313–322.
51.
Duberley RM, Johnson IP, Anand P, et al. Ciliary neurotrophic factor receptor expression in spinal cord and motor cortex in amyotrophic lateral sclerosis. J Neurol Sci 1995;129 Suppl:109–113.
Information & Authors
Information
Published In
Copyright
© 2006.
Publication History
Published online: January 18, 2006
Published in print: March 28, 2006
Authors
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- C9ORF72 Gene GGGGCC Hexanucleotide Expansion: A High Clinical Variability from Amyotrophic Lateral Sclerosis to Frontotemporal Dementia, Journal of Personalized Medicine, 13, 9, (1396), (2023).https://doi.org/10.3390/jpm13091396
- The Diagnostic Landscape of Adult Neurogenetic Disorders, Biology, 12, 12, (1459), (2023).https://doi.org/10.3390/biology12121459
- Advances in sequencing technologies for amyotrophic lateral sclerosis research, Molecular Neurodegeneration, 18, 1, (2023).https://doi.org/10.1186/s13024-022-00593-1
- Aspects of degradation and translation of the expanded C9orf72 hexanucleotide repeat RNA , Journal of Neurochemistry, 166, 2, (156-171), (2023).https://doi.org/10.1111/jnc.15847
- Susceptibility and disease modifier genes in amyotrophic lateral sclerosis: from genetic associations to therapeutic implications, Current Opinion in Neurology, 36, 4, (365-370), (2023).https://doi.org/10.1097/WCO.0000000000001178
- Non-motor symptoms in amyotrophic lateral sclerosis, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, (1-6), (2023).https://doi.org/10.1080/21678421.2023.2263868
- Circular RNA hsa_circ_0001846 facilitates the malignant behaviors of pancreatic cancer by sponging miR-204-3p and upregulating KRAS expression, Cell Death Discovery, 9, 1, (2023).https://doi.org/10.1038/s41420-023-01733-2
- New Approaches to the Treatment of Frontotemporal Dementia, Neurotherapeutics, 20, 4, (1055-1065), (2023).https://doi.org/10.1007/s13311-023-01380-6
- Towards Personalized Allele-Specific Antisense Oligonucleotide Therapies for Toxic Gain-of-Function Neurodegenerative Diseases, Pharmaceutics, 14, 8, (1708), (2022).https://doi.org/10.3390/pharmaceutics14081708
- Protein Aggregation in Neurodegenerative Diseases, Neurodegenerative Diseases: Multifactorial Degenerative Processes, Biomarkers and Therapeutic Approaches (First Edition), (26-58), (2022).https://doi.org/10.2174/9789815040913122010005
- See more
Loading...
View Options
Get Access
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
Purchase this article to get full access to it.